Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Comparison 8. Artesunate plus mefloquine vs Amodiaquine plus sulfadoxine-pyrimethamine<br />
Outcome or subgroup title<br />
No. of<br />
studies<br />
No. of<br />
participants Statistical method Effect size<br />
1 Total Failure (P. falciparum) Day<br />
28 PCR unadjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
1.1 Africa 1 300 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.15, 7.59]<br />
2 Total Failure (P. falciparum) Day<br />
28 PCR adjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
2.1 Africa 1 296 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
3 Gametocyte carriage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
3.1 Gametocyte carriage day 0 1 306 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.81]<br />
3.2 Gametocyte carriage day 3 1 306 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.06, 0.70]<br />
3.3 Gametocyte carriage day 7 1 306 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.47]<br />
3.4 Gametocyte carriage day<br />
14<br />
1 306 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
Comparison 9. Artemether-lumefantrine vs Artesunate plus amodiaquine<br />
Outcome or subgroup title<br />
No. of<br />
studies<br />
No. of<br />
participants Statistical method Effect size<br />
1 Total Failure (P. falciparum) Day<br />
28 PCR unadjusted<br />
9 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected<br />
1.1 East Africa 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
1.2 West Africa 5 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
1.3 South/Central Africa 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
2 Total Failure (P. falciparum) Day<br />
28 PCR adjusted<br />
8 1729 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.95, 2.87]<br />
2.1 East Africa 2 365 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.15, 4.59]<br />
2.2 West Africa 5 1245 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.00, 3.26]<br />
2.3 South/Central Africa 1 119 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
3 Gametocyte development 1 305 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.15, 0.74]<br />
4 Gametocyte carriage 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected<br />
4.1 Gametocyte carriage day 0 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
4.2 Gametocyte carriage day 3 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
4.3 Gametocyte carriage day 7 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
4.4 Gametocyte carriage day<br />
14<br />
2 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
5 Anaemia 5 Mean Difference (IV, Fixed, 95% CI) Totals not selected<br />
5.1 Mean haemoglobin (g/dl)<br />
at baseline<br />
4 Mean Difference (IV, Fixed, 95% CI) Not estimable<br />
5.2 Mean haemoglobin (g/dl)<br />
at Day 28<br />
1 Mean Difference (IV, Fixed, 95% CI) Not estimable<br />
5.3 Mean change in<br />
haemoglobin (g/dl) from<br />
baseline to Day 28<br />
1 Mean Difference (IV, Fixed, 95% CI) Not estimable<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
115